How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Sexually Transmitted Diseases Testing Market
- By Test Type: Nucleic Acid Amplification Tests (NAATs), Serological Tests, Rapid Diagnostic Tests (RDTs), Culture Tests, Microscopy Tests
- By Disease Type: Chlamydia, Gonorrhea, Syphilis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papillomavirus (HPV)
- By End User: Hospitals, Diagnostic Laboratories, Sexual Health Clinics, Home Testing Kits, Physician Offices
- By Sample Type: Urine Samples, Blood Samples, Swab Samples (Urethral, Vaginal, Throat), Saliva Samples
- By Testing Technology: Molecular Diagnostics, Immunoassays, Point-of-Care Testing, Enzyme-Linked Immunosorbent Assay (ELISA)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Nucleic Acid Amplification Tests (NAATs) leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Sexually Transmitted Diseases Testing Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Disease Type 6
End User 5
Sample Type 4
Testing Technology 4
Companies profiled
Abbott Laboratories
Roche Diagnostics
Hologic Inc.
Becton
Dickinson and Company (BD)
bioMérieux SA
Quidel Corporation
Siemens Healthineers
Thermo Fisher Scientific
Cepheid (a Danaher company)
F. Hoffmann-La Roche AG
Bio-Rad Laboratories
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →bioMérieux SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Quidel Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cepheid (a Danaher company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sekisui Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Orasure Technologies Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Gen-Probe (part of Hologic)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Alere Inc. (now part of Abbott)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,230M by 2033 · 3.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Nucleic Acid Amplification Tests (NAATs)45.2
- Serological Tests12.8
- Rapid Diagnostic Tests (RDTs)8.1
- Culture Tests16.4
- Microscopy Tests17.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,802M → $2,571M · 4.5%
Europe$1,256M → $1,674M · 3.7%
Asia Pacific$1,146M → $1,679M · 4.9%
Latin America$709.7M → $870.2M · 2.6%
Middle East and Africa$545.9M → $765.7M · 4.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.522026
3.532027
3.552028
3.562029
3.582030
3.582031
3.612032
3.612033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories18.7
- Roche Diagnostics15.7
- Hologic Inc.10.6
- Becton11.2
- Dickinson and Company (BD)8.6
- bioMérieux SA7.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type15.9%
Disease Type23.7%
End User28.4%
Sample Type14.5%
Testing Technology17.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe22.1
- Asia Pacific22.2
- Latin America11.5
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 74 | 92 | 87 | 96 | 82 | 98 | 88 |
| Roche Diagnostics | 88 | 79 | 88 | 81 | 72 | 83 | 82 |
| Hologic Inc. | 76 | 87 | 79 | 68 | 64 | 86 | 77 |
| Becton | 73 | 59 | 62 | 71 | 71 | 74 | 68 |
| Dickinson and Company (BD) | 56 | 62 | 54 | 57 | 71 | 59 | 60 |
| bioMérieux SA | 62 | 60 | 53 | 57 | 64 | 56 | 59 |
| Quidel Corporation | 42 | 60 | 56 | 62 | 51 | 46 | 53 |
| Siemens Healthineers | 37 | 47 | 38 | 40 | 48 | 53 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Roche Diagnostics
- Hologic Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Roche Diagnostics | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Hologic Inc. | ✓ | ✓ | ✓ | − | ✓ | ✓ |
| Becton | ✓ | ◐ | − | ◐ | − | ◐ |
| Dickinson and Company (BD) | − | ◐ | ◐ | − | ◐ | ◐ |
| bioMérieux SA | ◐ | ◐ | − | − | ✓ | ◐ |
| Quidel Corporation | − | ◐ | ◐ | − | ◐ | ◐ |
| Siemens Healthineers | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories88
2Roche Diagnostics82
3Hologic Inc.77
4Becton68
5Dickinson and Company (BD)60
6bioMérieux SA59
7Quidel Corporation53
8Siemens Healthineers44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesRoche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Hologic Inc.Becton
Contender2
Focused players with pockets of strength.
Dickinson and Company (BD)bioMérieux SA
Niche2
Specialists in a single segment or region.
Quidel CorporationSiemens Healthineers
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Sexually Transmitted Diseases Testing Market — a $380M beachhead inside a $6.10B market.
Beachhead (SOM)$380Mobtainable near-term
Serviceable (SAM)$2.14Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Nucleic Acid Amplification Tests (NAATs)
Best fit — highest urgency & budget in Test Type.
Economic buyer76 fit
Serological Tests
Strong fit — clear ROI and a fast path to value.
End user68 fit
Rapid Diagnostic Tests (RDTs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Sexually Transmitted Diseases Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation12%
Closed-won7%
$10.0KCAC
$43KLTV
4.3:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Sexually Transmitted Diseases Testing Market is a resilient opportunity — $1.55B by 2033, compounding at 4.7%.
TAM · 2025$1.08Btoday
TAM · 2033$1.55Bforecast
CAGR4.7%2027–2033
Cumulative$11.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.55BTotal addressable market
SAM$576MServiceable available market
SOM$107MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.55BLarge & growingTAM by 2033 at 4.7% CAGR
$576MServiceable nowreachable with today’s model
$107MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.21BBear3.0% CAGR
$1.55BBase4.7% CAGR
$1.99BBull6.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Sexually Transmitted Diseases Testing Market — a $3.77B market by 2033. Plan: grow share from 7.8% to 13.8%.
Market size · 2033$3.77Btotal addressable
Market CAGR8.4%2027–2033
Target share13.8%from 7.8% today
Revenue ambition$520Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 13.8% | Behind |
| Revenue | $267M | $520M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 37.3% | 42.2% | At risk |
| Customer retention | 86.8% | 96.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Type capability
A defensible second engine — invest in Disease Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $70M capacity & capability investment
- Greenlight bolt-on M&A in Disease Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Sexually Transmitted Diseases Testing Market conversation — a $3.26B market you can size, segment and defend in minutes.
Market size · 2033$3.26Btotal opportunity
Growth11.3%CAGR to 2033
Addressable buyers903+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 3 mopayback period
$40K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Abbott LaboratoriesRoche DiagnosticsHologic Inc.BectonDickinson and Company (BD)bioMérieux SAQuidel CorporationSiemens Healthineers+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Sexually Transmitted Diseases Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Sexually Transmitted Diseases Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Therapy Notes Software Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportMental Health Systems Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportTuberculosis Testing Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportJuvenile Health Insurance Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportVendor Neutral Archive (VNA) and PACS Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportUrology EMR and Billing Software Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportUrgent Care Apps Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportTesting, Inspection, and Certification for Life Sciences Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportSystem Integration Services Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportSmart Tattoo Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportPsychiatric Software System Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportPrescribed Health Apps Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.